Johnson & Johnson

In its 13F for Q4 2025 (holdings as of December 31, 2025, filed March 18, 2026), Johnson & Johnson reported 17 stock positions worth $555.0 million. Its top holding was Protagonist Therapeutics (PTGX) at 38.5% of the portfolio, followed by Nanobiotix SA - ADR (NBTX, 23.4%) and Rapport Therapeutics (RAPP, 9.8%). Compared with Q3 2025, it opened 2 new positions, sold out of 5 and reduced 1. The biggest buy was a new position in Vor Biopharma (VOR) and the biggest sale an exit from Arrowhead Pharmaceuticals (ARWR).

Most Recent 13F
Q2 2026
Location
NEW BRUNSWICK, NJ
CIK
0000200406
Portfolio Value
$555.0M (Q4 2025)
SEC Filing
0000904454-26-000192 ↗ filed Mar 18, 2026

Holdings Value

0$1.0B$2.0B$3.0B$4.0B$5.0B Q1 2024: $4.4B Q1 2024 Q2 2024: $400.7M Q2 2024 Q3 2024: $427.3M Q3 2024 Q4 2024: $386.1M Q4 2024 Q1 2025: $341.9M Q1 2025 Q2 2025: $334.1M Q2 2025 Q3 2025: $503.9M Q3 2025 Q4 2025: $555.0M $555.0M Q4 2025 Q1 2026: $652.4M Q1 2026 Q2 2026: $798.7M Q2 2026

Holdings 17 stocks · $555.0M
PTGX Protagonist Therapeutics Inc. 38.54% 2,449,183 $213.9M No change
NBTX Nanobiotix SA - ADR 23.43% 5,623,816 $130.0M No change
RAPP Rapport Therapeutics Inc. 9.75% 1,784,517 $54.1M No change
MGTX Meiragtx Holdings PLC 9.51% 6,641,064 $52.8M No change
CVRX CVRX Inc. 5.15% 4,024,861 $28.6M Reduce -1.9%
CTNM Contineum Therapeutics Inc. Class A 4.08% 1,979,173 $22.6M No change
LEGN Legend Biotech Corp.-ADR 3.19% 814,586 $17.7M No change
XNCR Xencor Inc. 2.06% 748,062 $11.5M No change
PRCT Procept Biorobotics Corp. 2.03% 357,939 $11.3M No change
FATE Fate Therapeutics Inc. 0.60% 3,379,064 $3.3M No change
NMRA Neumora Therapeutics Inc. 0.60% 1,849,445 $3.3M No change
RLYB Rallybio Corp. 0.45% 3,636,363 $2.5M No change
LYEL Lyell Immunopharma Inc. 0.30% 54,887 $1.7M No change
VOR Vor Biopharma Inc. 0.13% 53,732 $703K New
NNOX Nano-X Imaging Ltd. 0.08% 158,852 $445K No change
LAB Standard Biotools Inc. 0.07% 311,967 $399K No change
ACET Adicet Bio Inc. 0.03% 22,779 $192K New

Portfolio Sells Q3 2025 → Q4 2025
ARWR Arrowhead Pharmaceuticals Inc. Sold out 0.00% −1.69
CVRX CVRX Inc. Reduce -1.9% 5.15% −1.42
VOR Vor Biopharma Inc. Sold out 0.00% −0.52
ACET Adicet Bio Inc. Sold out 0.00% −0.06
BIOMX INC Sold out 0.00% −0.01
SENS Senseonics Holdings Inc. Sold out 0.00% −0.00

Portfolio Buys Q3 2025 → Q4 2025
VOR Vor Biopharma Inc. New 0.13% +0.13
ACET Adicet Bio Inc. New 0.03% +0.03

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 15$798.7MPTGX, NBTX, MGTX, RAPP, CTNM
Q1 2026 16$652.4MPTGX, NBTX, MGTX, RAPP, CVRX
Q4 2025Amended 17$555.0MPTGX, NBTX, RAPP, MGTX, CVRX
Q3 2025Amended 20$503.9MPTGX, NBTX, MGTX, RAPP, CVRX
Q2 2025 20$334.1MPTGX, MGTX, RAPP, LEGN, NBTX
Q1 2025 20$341.9MPTGX, CVRX, MGTX, LEGN, RAPP
Q4 2024 20$386.1MPTGX, CVRX, RAPP, MGTX, CTNM
Q3 2024 20$427.3MPTGX, RAPP, LEGN, CTNM, CVRX
Q2 2024 20$400.7MPTGX, RAPP, CVRX, LEGN, CTNM
Q1 2024 22$4.4BKVUE, FUSN, CVRX, PTGX, SWAV